Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
暂无分享,去创建一个
G. Martiny-Baron | J. Wood | J. Drevs | D. Marmé | C. Unger | M. Müller | M Müller | C Unger | H Madjar | H. Madjar | I. Hofmann | G Martiny-Baron | D Marmé | J Drevs | I Hofmann | H Hugenschmidt | C Wittig | J Wood | H. Hugenschmidt | C. Wittig | M. Müller
[1] M. Karno,et al. Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.
[2] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[3] J. Mestan,et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. , 2000, Cancer research.
[4] T. Morita,et al. Antitumour effect of a synthetic analogue of fumagillin on murine renal carcinoma. , 1994, British journal of urology.
[5] W. Sauerbrei,et al. Color Doppler flow criteria of breast lesions. , 1994, Ultrasound in medicine & biology.
[6] S. Påhlman,et al. The Angiogenesis Inhibitor TNP-470 Reduces the Growth Rate of Human Neuroblastoma in Nude Rats , 1997, Pediatric Research.
[7] J. Drevs,et al. Angiogenesis Inhibition: Drugs in Clinical Trials , 1999, Oncology Research and Treatment.
[8] A. Uchida,et al. Suppression of pulmonary metastasis by angiogenesis inhibitor TNP‐470 in murine osteosarcoma , 1995, International journal of cancer.
[9] C. Verschraegen,et al. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. , 1998, The New England journal of medicine.
[10] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[11] R. Wiltrout,et al. Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes. , 1986, Cancer research.
[12] G. Haas,et al. Experimental animal models for the study of therapeutic approaches in renal cell carcinoma. , 1994, In vivo.
[13] T. Sayers,et al. Antitumor Effects of α-Interferon and γ-Interferon on a Murine Renal Cancer (Renca) in Vitro and in Vivo , 1990 .
[14] J. Drevs,et al. In Vivo and In Vitro Efficacy of an Acid-Sensitive Albumin Conjugate of Adriamycin Compared to the Parent Compound in Murine Renal-Cell Carcinoma , 1999 .
[15] D. Marm,et al. Tumor angiogenesis: the pivotal role of vascular endothelial growth factor , 2004, World Journal of Urology.
[16] J. Folkman,et al. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. , 1986, Cancer research.
[17] FUMAGILLIN ANALOG (TNP-470) IN THE TREATMENT OF KAPOSI'S SARCOMA: A PHASE I AIDS CLINICAL TRIAL GROUP STUDY , 1997 .
[18] P. Wingo,et al. Cancer statistics, 1996 , 1996, CA: a cancer journal for clinicians.
[19] D. Lindner,et al. Effects of tamoxifen and interferon‐β or the combination on tumor‐induced angiogenesis , 1997, International journal of cancer.